On November 25, the FANGZHOU JIANKE (06086) Double 12 Core Partners Summit (hereafter referred to as the Partners Summit) was successfully held in Guangzhou. Centered on the theme "Synergy for Shared Success, Intelligence Leading the Future," the summit brought together industry experts, partners, and frontline practitioners to explore pathways for enhancing chronic disease management efficiency through artificial intelligence (AI).
A highlight of the event was the signing of a strategic collaboration agreement between FANGZHOU JIANKE and Suzhou VIGONVITA Biopharmaceutical Co., Ltd. (VIGONVITA-B, 02630). This partnership exemplifies the integration of core industry resources and digital intelligence capabilities, aiming to drive innovation in AI-powered chronic disease management. The collaboration will focus on product pipeline development and digital marketing, injecting momentum into the high-quality growth of the healthcare sector.
**AI + Chronic Disease Management: Technology-Driven Growth** On October 24, China’s Ministry of Science and Technology emphasized the nationwide implementation of the "AI +" initiative to transform industries. On November 4, the National Health Commission issued guidelines to promote and standardize AI applications in healthcare, outlining a five-year roadmap for medical AI development.
Against this policy backdrop, Dr. Xie Fangmin, Founder, Chairman, and CEO of FANGZHOU JIANKE, highlighted the opportunities arising from technological advancements. "AI + healthcare is a critical frontier, especially amid China’s aging population and rising chronic disease prevalence among younger demographics," he noted. FANGZHOU JIANKE’s "AI Health Assistant" platform exemplifies this approach, with October data showing a 2.4x increase in user engagement and a 50% surge in GMV compared to September.
Dr. Xie stressed that AI must address real-world challenges, such as gaps in hospital and home-based care, while fostering industry-wide collaboration to develop scalable digital solutions.
**Strategic Synergy: Full-Chain Digital Transformation** The partnership between FANGZHOU JIANKE and VIGONVITA-B merges the former’s AI and full-chain service capabilities with the latter’s biopharmaceutical R&D expertise. Together, they aim to create a patient-centric health ecosystem, delivering precise, efficient, and professional chronic disease management solutions.
Dr. Tian Guanghui, Chairman and General Manager of VIGONVITA-B, expressed optimism about the collaboration: "FANGZHOU JIANKE’s achievements in AI-driven chronic disease management align with our mission. This partnership bridges R&D and service delivery, ensuring innovative therapies and digital health solutions reach more households."
As China’s "AI +" strategy gains clarity, the Partners Summit not only showcased FANGZHOU JIANKE’s leadership in AI-powered healthcare but also laid the groundwork for industry-wide digital transformation. Moving forward, FANGZHOU JIANKE will continue advancing chronic disease management through technology, fostering a smarter, more inclusive healthcare future with its partners.